Vybrique Film
Product Images NDC 71858-0205

Product Visual Gallery

This gallery contains 25 technical images submitted to the FDA as part of the official labeling for Vybrique (NDC 71858-0205). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ibsa Pharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Sildenafil Citrate Is Designated Chemically As 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine Citrate, Has The Molecular Formu (Vybrique Sildenafil Citrate Oral Film 01)

Chemical structure of sildenafil citrate, the active ingredient in Vybrique oral film tablets.*

FDA Label Image

Figure 1 (Vybrique Sildenafil Citrate Oral Film 02)

Line graph depicting systolic blood pressure (mmHg) over time (hours) in young volunteers (18-45 years). It compares Sildenafil 100 mg oral film to placebo from pre-dose up to 10 hours post-dose, showing changes in systolic blood pressure for each group.*

FDA Label Image

Figure 2 (Vybrique Sildenafil Citrate Oral Film 03)

A line graph showing systolic blood pressure (mmHg) over time (hours) in elderly (≥ 65 years) volunteers. The graph compares two groups: one receiving sildenafil 100 mg oral film and the other receiving placebo. The sildenafil group shows generally lower systolic blood pressure values compared to the placebo group throughout the 10-hour period.*

FDA Label Image

Figure 3 (Vybrique Sildenafil Citrate Oral Film 04)

A line graph showing the change in systolic blood pressure (SBP) over 8 hours postdose. The graph compares two treatments: Doxazosin + Placebo and Doxazosin + Sildenafil 25 mg. The y-axis represents the change in SBP (mmHg) and the x-axis represents time in hours postdose. The graph includes markers and lines for both treatment groups.*

FDA Label Image

Figure 4 (Vybrique Sildenafil Citrate Oral Film 05)

Line graph depicting change in systolic blood pressure (mmHg) over time (hours) postdose. Two data series compare the effects of Doxazosin combined with Placebo versus Doxazosin combined with Sildenafil 50 mg, showing trends of blood pressure changes within an 8-hour postdose period.*

FDA Label Image

Figure 5 (Vybrique Sildenafil Citrate Oral Film 06)

A line graph depicting the effect of dosing over time (hours) with two groups: Doxazosin plus Sildenafil 100 mg and Doxazosin plus Placebo. The vertical axis represents a measurement in mmHg, ranging approximately from -50 to 30, and the horizontal axis shows time after dosing from 0 to 8 hours.*

FDA Label Image

Figure 6 (Vybrique Sildenafil Citrate Oral Film 07)

A pharmacokinetic curve showing drug concentration (ng/mL) on the y-axis versus time (hours) on the x-axis. The graph depicts a rapid increase in concentration peaking around 2 hours, followed by a gradual decline over 24 hours.*

FDA Label Image

Figure 7 (Vybrique Sildenafil Citrate Oral Film 08)

A pair of bar graphs comparing the effect of sildenafil and placebo on patients using the Rascina score. The left graph titled 'Effect of Sildenafil' shows the percentage of patients at each Rascina score from 0 to 5, with increasing scores associated with higher patient percentages, particularly for scores 4 and 5. The right graph titled 'Effect of Placebo' displays a more varied distribution of patient percentages across scores 0 to 5. Both graphs use a legend indicating score categories from 0 to 5.*

FDA Label Image

Figure 8 (Vybrique Sildenafil Citrate Oral Film 09)

A bar chart depicting the percentage of patients reporting improvement across different treatment groups. The groups include Placebo, Sildenafil Citrate 25 mg, 50 mg, and 100 mg, with reported improvement percentages of 24%, 63%, 74%, and 82% respectively. The chart compares efficacy by dosage in a clinical setting.*

FDA Label Image

A (Vybrique Sildenafil Citrate Oral Film 0a)

An illustration showing a hand holding a rectangular-shaped film strip, likely representing the oral film dosage form of Vybrique (sildenafil citrate). The image demonstrates how the film may be held prior to administration.*

FDA Label Image

B (Vybrique Sildenafil Citrate Oral Film 0b)

Illustration showing hands peeling back the backing of a film strip, likely demonstrating how to open or handle a film dosage form.*

FDA Label Image

C (Vybrique Sildenafil Citrate Oral Film 0c)

An instructional illustration showing two hands stretching an oral film product, possibly demonstrating how to handle or apply Vybrique oral film containing sildenafil citrate.*

FDA Label Image

D (Vybrique Sildenafil Citrate Oral Film 0d)

An instructional illustration showing a person placing an oral film dosage form on their tongue. The film is being held by the person's hand near their mouth, demonstrating the proper method of administration.*

FDA Label Image

Principal Display Panelndc 71858-0205-5vybrique(sildenafil) Oral Film25 mg Per Oral Film4 Oral Filmsrx (Vybrique Sildenafil Citrate Oral Film 0e)

The image shows the packaging label for Vybrique 25 mg oral film containing sildenafil citrate. The label indicates the dosage form as a 25 mg per oral film and specifies a net quantity of 4 oral films. It includes inactive ingredients and usage instructions, with IBSA Pharma Inc. as the labeler. The label features barcodes and regulatory information.*

FDA Label Image

Principal Display Panelndc 71858-0205-6vybrique(sildenafil) Oral Film25 mg Per Oral Film8 Oral Filmsrx (Vybrique Sildenafil Citrate Oral Film 0f)

Packaging label for Vybrique sildenafil oral film 25 mg by IBSA Pharma Inc. The label indicates that each oral film contains 25 mg of sildenafil citrate. The package contains 8 oral films and includes storage instructions as well as inactive ingredients. The design features blue and beige accents with clear branding and regulatory information.*

FDA Label Image

Principal Display Panelndc 71858-0205-4vybrique(sildenafil) Oral Film25 mg Per Oral Film1 Oral Filmsrx (Vybrique Sildenafil Citrate Oral Film 10)

Packaging label for Vybrique 25 mg oral film containing sildenafil citrate, distributed by IBSA Pharma Inc. The front label includes the dosage strength and directions to store the light blue oral film in the pouch until use. The back label provides active ingredient information, dosage reference, lot number, expiration date, and a barcode.*

FDA Label Image

Principal Display Panelndc 71858-0210-5vybrique(sildenafil) Oral Film50 mg Per Oral Film4 Oral Filmsrx (Vybrique Sildenafil Citrate Oral Film 11)

Packaging label for Vybrique 50 mg oral film containing sildenafil citrate. The blue and white carton displays the proprietary and generic name, strength, dosage form, and quantity of 4 oral films. Labeler IBSA Pharma Inc. is noted, along with inactive ingredients and usage instructions.*

FDA Label Image

Principal Display Panelndc 71858-0210-6vybrique(sildenafil) Oral Film50 mg Per Oral Film8 Oral Filmsrx (Vybrique Sildenafil Citrate Oral Film 12)

Vybrique 50 mg oral film packaging label showing sildenafil citrate as the active ingredient. The label includes the dosage strength of 50 mg per oral film and indicates the package contains 8 oral films. The labeler is IBSA Pharma Inc. The design features a blue and white color scheme with barcodes and storage instructions.*

FDA Label Image

Principal Display Panelndc 71858-0210-4vybrique(sildenafil) Oral Film50 mg Per Oral Film1 Oral Filmsrx (Vybrique Sildenafil Citrate Oral Film 13)

Packaging label for Vybrique sildenafil citrate oral film, 50 mg strength. The label shows the product name, strength, dosage form as oral film, and storage instruction to keep the light blue oral film in the pouch until use. It is distributed by IBSA Pharma Inc. The reverse side includes dosage information, prescribing reference, distribution statement, lot and expiration fields, and a barcode.*

FDA Label Image

Principal Display Panelndc 71858-0215-5vybrique(sildenafil) Oral Film75 mg Per Oral Film4 Oral Filmsrx (Vybrique Sildenafil Citrate Oral Film 14)

Vybrique 75 mg sildenafil oral film packaging label by IBSA Pharma Inc. The label indicates the product is a prescription oral film with 75 mg sildenafil citrate per film. The package contains 4 oral films and lists inactive ingredients and distributor details. The label also includes storage instructions and barcodes.*

FDA Label Image

Principal Display Panelndc 71858-0215-6vybrique(sildenafil) Oral Film75 mg Per Oral Film8 Oral Filmsrx (Vybrique Sildenafil Citrate Oral Film 15)

Packaging label for Vybrique 75 mg sildenafil oral film by IBSA Pharma Inc. The label shows the product name, strength (75 mg per oral film), dosage form as oral film, and the quantity of 8 oral films. It includes inactive ingredients and storage instructions. The label states the product is prescription only and made in Italy, with distributor information for IBSA Pharma Inc.*

FDA Label Image

Principal Display Panelndc 71858-0215-4vybrique(sildenafil) Oral Film75 mg Per Oral Film1 Oral Filmsrx (Vybrique Sildenafil Citrate Oral Film 16)

Packaging label for Vybrique sildenafil oral film, 75 mg strength. The label indicates it is a prescription-only oral film product distributed by IBSA Pharma Inc. It instructs to store the light blue oral film in the pouch until use. The back lists sildenafil citrate content per film and notes dosing information is in the prescribing info, with space for lot and expiration dates.*

FDA Label Image

Principal Display Panelndc 71858-0220-5vybrique(sildenafil) Oral Film100 mg Per Oral Film4 Oral Filmsrx (Vybrique Sildenafil Citrate Oral Film 17)

The unfolded packaging label for Vybrique 100 mg oral film, containing sildenafil citrate by IBSA Pharma Inc. The label shows the product name, strength (100 mg), dosage form (oral film), and net quantity of 4 oral films. Includes storage instructions, inactive ingredients list, and distributor information (IBSA Pharma Inc., Parsippany, NJ). The label prominently features the Rx only symbol and a blue and white color scheme.*

FDA Label Image

Principal Display Panelndc 71858-0220-6vybrique(sildenafil) Oral Film100 mg Per Oral Film8 Oral Filmsrx (Vybrique Sildenafil Citrate Oral Film 18)

Vybrique 100 mg sildenafil oral film packaging label by IBSA Pharma Inc. The label indicates it contains 8 oral films, each with 100 mg of sildenafil citrate. It specifies the film form, oral route, and includes inactive ingredients, storage instructions, and distributor information. The label also notes the product is made in Italy and is a prescription drug.*

FDA Label Image

Principal Display Panelndc 71858-0220-4vybrique(sildenafil) Oral Film100 mg Per Oral Film1 Oral Filmsrx (Vybrique Sildenafil Citrate Oral Film 19)

The image shows front and back views of the Vybrique sildenafil oral film 100 mg packaging label. The front label includes the product name, strength, dosage form, dose per film, storage instructions, and the IBSA Pharma Inc. logo. The back label details the active ingredient amount per film, dosage guidance, distributor, lot, expiration fields, and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.